Psoriasis and Its Impact on In-Hospital Outcome in Patients Hospitalized with Acute Kidney Injury
Abstract
:1. Introduction
2. Patients and Methods
2.1. Data Source
2.2. Diagnoses, Procedural and Diagnostic Codes, and Definitions
2.3. Coded Parameters and Study Outcomes
2.4. Ethical Aspects
2.5. Statistical Methods
3. Results
3.1. Baseline Characteristics
3.2. Impact of Psoriasis on In-Hospital Mortality in Patients Hospitalized for AKI
3.3. Renal Replacement Therapy and Type of Procedure
3.4. Trends between 2005 and 2016
4. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Boehncke, W.H.; Schon, M.P. Psoriasis. Lancet 2015, 386, 983–994. [Google Scholar] [CrossRef]
- Rachakonda, T.D.; Schupp, C.W.; Armstrong, A.W. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014, 70, 512–516. [Google Scholar] [CrossRef] [PubMed]
- Kridin, K.; Ludwig, R.J.; Damiani, G.; Cohen, A.D. Increased Risk of Pemphigus among Patients with Psoriasis: A Large-scale Cohort Study. Acta Dermato-Venereologica. 2020. [Google Scholar] [CrossRef] [PubMed]
- Kridin, K.; Vanetik, S.; Damiani, G.; Cohen, A.D. Big data highlights the association between psoriasis and fibromyalgia: A population-based study. Immunol. Res. 2020, 68, 135–140. [Google Scholar] [CrossRef]
- Damiani, G.; Pacifico, A.; Rizzi, M.; Santus, P.; Bridgewood, C.; Bragazzi, N.L.; Adawi, M.; Watad, A. Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. Clin. Rheumatol. 2020. [Google Scholar] [CrossRef]
- Conic, R.R.; Damiani, G.; Schrom, K.P.; Ramser, A.E.; Zheng, C.; Xu, R.; McCormick, T.S.; Cooper, K.D. Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. J. Clin. Med. 2020, 9, 186. [Google Scholar] [CrossRef] [Green Version]
- Watad, A.; Bragazzi, N.L.; McGonagle, D.; Damiani, G.; Comaneshter, D.; Cohen, A.; Amital, H. Systemic Sclerosis is Linked to Psoriasis and May Impact on Patients’ Survival: A Large Cohort Study. J. Clin. Med. 2019, 8, 521. [Google Scholar] [CrossRef] [Green Version]
- Sommer, D.M.; Jenisch, S.; Suchan, M.; Christophers, E.; Weichenthal, M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006, 298, 321–328. [Google Scholar] [CrossRef]
- Bacaksiz, A.; Erdogan, E.; Sonmez, O.; Sevgili, E.; Tasal, A.; Onsun, N.; Topukcu, B.; Kulac, B.; Uysal, O.; Goktekin, O. Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2013, 19, 501–509. [Google Scholar] [CrossRef] [Green Version]
- Armstrong, A.W.; Harskamp, C.T.; Armstrong, E.J. The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies. J. Hypertens. 2013, 31, 433–442. [Google Scholar] [CrossRef]
- Mehta, N.N.; Azfar, R.S.; Shin, D.B.; Neimann, A.L.; Troxel, A.B.; Gelfand, J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur. Heart J. 2010, 31, 1000–1006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armstrong, E.J.; Harskamp, C.T.; Armstrong, A.W. Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies. J. Am. Heart Assoc. 2013, 2, e000062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seth, D.; Ehlert, A.N.; Golden, J.B.; Damiani, G.; McCormick, T.S.; Cameron, M.J.; Cooper, K.D. Interaction of Resistin and Systolic Blood Pressure in Psoriasis Severity. J. Investig. Dermatol. 2020, 140, 1279–1282. [Google Scholar] [CrossRef] [PubMed]
- Ghiasi, M.; Nouri, M.; Abbasi, A.; Hatami, P.; Abbasi, M.A.; Nourijelyani, K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J. Dermatol. 2011, 56, 533–536. [Google Scholar] [CrossRef]
- Miller, I.M.; Ellervik, C.; Yazdanyar, S.; Jemec, G.B. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J. Am. Acad. Dermatol. 2013, 69, 1014–1024. [Google Scholar] [CrossRef]
- Elnabawi, Y.A.; Dey, A.K.; Goyal, A.; Groenendyk, J.W.; Chung, J.H.; Belur, A.D.; Rodante, J.; Harrington, C.L.; Teague, H.L.; Baumer, Y.; et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study. Cardiovasc. Res. 2019, 115, 721–728. [Google Scholar] [CrossRef]
- Zachariae, H.; Grunnet, E.; Sogaard, H. Accidental kidney biopsies in psoriasis. Br. J. Dermatol. 1976, 94, 655–657. [Google Scholar] [CrossRef]
- Singh, N.P.; Prakash, A.; Kubba, S.; Ganguli, A.; Singh, A.K.; Sikdar, S.; Agarwal, S.K.; Dinda, A.K.; Grover, C. Psoriatic nephropathy-does an entity exist? Ren. Fail. 2005, 27, 123–127. [Google Scholar]
- Szepietowski, J.C.; Szepietowski, T. Is renal function altered in patients with psoriasis vulgaris?-A short review. J. Dermatol. 2000, 27, 569–572. [Google Scholar] [CrossRef]
- Abuabara, K.; Azfar, R.S.; Shin, D.B.; Neimann, A.L.; Troxel, A.B.; Gelfand, J.M. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. Br. J. Dermatol. 2010, 163, 586–592. [Google Scholar] [CrossRef] [Green Version]
- Li, P.K.; Burdmann, E.A.; Mehta, R.L. Acute kidney injury: Global health alert. Kidney Int. 2013, 83, 372–376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murugan, R.; Kellum, J.A. Acute kidney injury: What’s the prognosis? Nat. Rev. Nephrol. 2011, 7, 209–217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Keller, K.; Hobohm, L.; Ebner, M.; Kresoja, K.P.; Munzel, T.; Konstantinides, S.V.; Lankeit, M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur. Heart J. 2019. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hobohm, L.; von Bardeleben, R.S.; Ostad, M.A.; Wenzel, P.; Munzel, T.; Gori, T.; Keller, K. 5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany. JACC Cardiovasc. Interv. 2019, 12, 1044–1052. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Coresh, J.; Tighiouart, H.; Greene, T.; Inker, L.A. Strengths and limitations of estimated and measured GFR. Nat. Rev. Nephrol. 2019, 15, 784. [Google Scholar] [CrossRef]
- Porrini, E.; Ruggenenti, P.; Luis-Lima, S.; Carrara, F.; Jimenez, A.; de Vries, A.P.J.; Torres, A.; Gaspari, F.; Remuzzi, G. Estimated GFR: Time for a critical appraisal. Nat. Rev. Nephrol. 2019, 15, 177–190. [Google Scholar] [CrossRef]
- Costa-Silva, M.; Vide, J.; Lopes, S.; Azevedo, F.; Magina, S. Psoriasis and comorbidities: General practitioners’ awareness. Acta Dermatovenerol. Alp. Pannonica Adriat. 2018, 27, 5–7. [Google Scholar]
- Parsi, K.K.; Brezinski, E.A.; Lin, T.C.; Li, C.S.; Armstrong, A.W. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. J. Am. Acad. Dermatol. 2012, 67, 357–362. [Google Scholar] [CrossRef]
- Damiani, G.; Watad, A.; Bridgewood, C.; Pigatto, P.D.M.; Pacifico, A.; Malagoli, P.; Bragazzi, N.L.; Adawi, M. The Impact of Ramadan Fasting on the Reduction of PASI Score, in Moderate-To-Severe Psoriatic Patients: A Real-Life Multicenter Study. Nutrients 2019, 11, 277. [Google Scholar] [CrossRef] [Green Version]
- Kocic, H.; Damiani, G.; Stamenkovic, B.; Tirant, M.; Jovic, A.; Tiodorovic, D.; Peris, K. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther. Adv. Chronic Dis. 2019, 10, 2040622319864805. [Google Scholar] [CrossRef] [Green Version]
- Ricketts, J.R.; Rothe, M.J.; Grant-Kels, J.M. Nutrition and psoriasis. Clin. Dermatol. 2010, 28, 615–626. [Google Scholar] [CrossRef] [PubMed]
- Balato, N.; Megna, M.; Palmisano, F.; Patruno, C.; Napolitano, M.; Scalvenzi, M.; Ayala, F. Psoriasis and sport: A new ally? J. Eur. Acad. Dermatol. Venereol. JEADV 2015, 29, 515–520. [Google Scholar] [CrossRef] [PubMed]
- Kaye, J.A.; Li, L.; Jick, S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 2008, 159, 895–902. [Google Scholar] [CrossRef]
- Shah, K.; Mellars, L.; Changolkar, A.; Feldman, S.R. Real-world burden of comorbidities in US patients with psoriasis. J. Am. Acad. Dermatol. 2017, 77, 287–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armstrong, A.W.; Harskamp, C.T.; Armstrong, E.J. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol. 2013, 149, 84–91. [Google Scholar] [CrossRef]
- Qureshi, A.A.; Choi, H.K.; Setty, A.R.; Curhan, G.C. Psoriasis and the risk of diabetes and hypertension: A prospective study of US female nurses. Arch. Dermatol. 2009, 145, 379–382. [Google Scholar] [CrossRef] [Green Version]
- Cartin-Ceba, R.; Kashiouris, M.; Plataki, M.; Kor, D.J.; Gajic, O.; Casey, E.T. Risk factors for development of acute kidney injury in critically ill patients: A systematic review and meta-analysis of observational studies. Crit. Care Res. Pract. 2012, 2012, 691013. [Google Scholar] [CrossRef]
- Thakar, C.V.; Christianson, A.; Himmelfarb, J.; Leonard, A.C. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin. J. Am. Soc. Nephrol. CJASN 2011, 6, 2567–2572. [Google Scholar] [CrossRef]
- Lin, H.W.; Wang, K.H.; Lin, H.C.; Lin, H.C. Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan. J. Am. Acad. Dermatol. 2011, 64, 495–501. [Google Scholar] [CrossRef]
- Levesque, A.; Lachaine, J.; Bissonnette, R. Risk of myocardial infarction in canadian patients with psoriasis: A retrospective cohort study. J. Cutan. Med. Surg. 2013, 17, 398–403. [Google Scholar] [CrossRef]
- Gelfand, J.M.; Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296, 1735–1741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shiba, M.; Kato, T.; Izumi, T.; Miyamoto, S.; Nakane, E.; Haruna, T.; Inoko, M. Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital. J. Cardiol. 2019, 73, 276–279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, J.J.; Choi, Y.M.; Bebchuk, J.D. Risk of myocardial infarction in psoriasis patients: A retrospective cohort study. J. Dermatol. Treat. 2015, 26, 230–234. [Google Scholar] [CrossRef] [PubMed]
- Ungprasert, P.; Sanguankeo, A.; Upala, S.; Suksaranjit, P. Psoriasis and risk of venous thromboembolism: A systematic review and meta-analysis. QJM Mon. J. Assoc. Physicians 2014, 107, 793–797. [Google Scholar] [CrossRef] [Green Version]
- Ogdie, A.; Kay McGill, N.; Shin, D.B.; Takeshita, J.; Jon Love, T.; Noe, M.H.; Chiesa Fuxench, Z.C.; Choi, H.K.; Mehta, N.N.; Gelfand, J.M. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A general population-based cohort study. Eur. Heart J. 2018, 39, 3608–3614. [Google Scholar] [CrossRef] [Green Version]
- Takeshita, J.; Mohler, E.R.; Krishnamoorthy, P.; Moore, J.; Rogers, W.T.; Zhang, L.; Gelfand, J.M.; Mehta, N.N. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J. Am. Heart Assoc. 2014, 3, e000507. [Google Scholar] [CrossRef] [Green Version]
- Karbach, S.; Croxford, A.L.; Oelze, M.; Schuler, R.; Minwegen, D.; Wegner, J.; Koukes, L.; Yogev, N.; Nikolaev, A.; Reissig, S.; et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 2658–2668. [Google Scholar] [CrossRef] [Green Version]
- Mehta, N.N.; Shin, D.B.; Joshi, A.A.; Dey, A.K.; Armstrong, A.W.; Duffin, K.C.; Fuxenchm, Z.C.; Harrington, C.L.; Hubbard, R.A.; Kalb, R.E.; et al. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ. Cardiovasc. Imaging 2018, 11, e007394. [Google Scholar] [CrossRef] [Green Version]
- Daghem, M.; Newby, D. Psoriasis and Inflammation More Than Skin Deep. Circ. Cardiovasc. Imaging 2018, 11, e007849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farmer, C.K.; Stevens, P.E. Chronic kidney disease: Psoriasis-a risk factor for chronic kidney disease? Nat. Rev. Nephrol. 2014, 10, 12–13. [Google Scholar] [CrossRef]
- Madeddu, P.; Ena, P.; Glorioso, N.; Cerimele, D.; Rappelli, A. High prevalence of microproteinuria, an early index of renal impairment, in patients with diffuse psoriasis. Nephron 1988, 48, 222–225. [Google Scholar] [CrossRef] [PubMed]
- Cassano, N.; Vestita, M.; Panaro, M.; Carbonara, M.; Vena, G.A. Renal function in psoriasis patients. Eur. J. Dermatol. EJD 2011, 21, 264–265. [Google Scholar] [CrossRef] [PubMed]
- Caiazzo, G.; Fabbrocini, G.; Di Caprio, R.; Raimondo, A.; Scala, E.; Balato, N.; Balato, A. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front. Immunol. 2018, 9, 1668. [Google Scholar] [CrossRef] [Green Version]
- Damiani, G.; Conic, R.R.Z.; Pigatto, P.D.M.; Bragazzi, N.L.; Pacifico, A.; Malagoli, P. Young Dermatologists Italian, N. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol. Ther. 2019, 32, e12886. [Google Scholar] [CrossRef]
- Damiani, G.; Conic, R.R.Z.; de Vita, V.; Costanzo, A.; Regazzini, R.; Pigatto, P.D.M.; Bragazzi, N.L.; Pacifico, A.; Malagoli, P. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol. Ther. 2019, 32, e12793. [Google Scholar] [CrossRef]
- Ahlehoff, O. Psoriasis and Cardiovascular Disease: Epidemiological studies. Dan. Med. Bull. 2011, 58, B4347. [Google Scholar]
- Gelfand, J.M.; Troxel, A.B.; Lewis, J.D.; Kurd, S.K.; Shin, D.B.; Wang, X.; Margolis, D.J.; Strom, B.L. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch. Dermatol. 2007, 143, 1493–1499. [Google Scholar] [CrossRef]
Parameters | All Patients (n = 3,162,449) | AKI with Psoriasis (n = 11,985; 0.4%) | AKI without Psoriasis (n = 3,150,464; 99.6%) | p-Value |
---|---|---|---|---|
Age (years) | 76 (67–83) | 70 (60–78) | 76 (67–83) | <0.001 |
Sex (female) | 1,449,815 (45.8%) | 4750 (39.6%) | 1,445,065 (45.9%) | <0.001 |
Obesity | 279,170 (8.8%) | 2312 (19.3%) | 276,858 (8.8%) | <0.001 |
Comorbidities | ||||
Coronary artery disease | 813,696 (25.7%) | 3204 (26.7%) | 810,492 (25.7%) | 0.012 |
Malignancy | 541,108 (17.1%) | 1463 (12.2%) | 539,645 (17.1%) | <0.001 |
Heart failure | 1,158,990 (36.6%) | 4508 (37.6%) | 1,154,482 (36.6%) | 0.028 |
Chronic obstructive pulmonary disease | 404,619 (12.8%) | 2175 (18.1%) | 402,444 (12.8%) | <0.001 |
Diabetes mellitus | 1,112,335 (35.2%) | 5099 (42.5%) | 1,107,236 (35.1%) | <0.001 |
Essential arterial hypertension | 1,425,566 (45.1%) | 6102 (50.9%) | 1,419,464 (45.1%) | <0.001 |
Atrial fibrillation/-flutter | 985,758 (31.2%) | 3660 (30.5%) | 982,098 (31.2%) | 0.136 |
Deep vein thrombosis or thrombophlebitis | 55,618 (1.8%) | 274 (2.3%) | 55,344 (1.8%) | <0.001 |
Chronic kidney disease Stage 1 | 63,514 (2.0%) | 267 (2.2%) | 63,247 (2.0%) | 0.088 |
Stage 2 | 139,711 (4.4%) | 709 (5.9%) | 139,002 (4.4%) | <0.001 |
Stage 3 | 573,569 (18.1%) | 2380 (19.9%) | 571,189 (18.1%) | <0.001 |
Stage 4 | 261,616 (8.3%) | 971 (8.1%) | 260,645 (8.3%) | 0.506 |
Stage 5 | 109,487 (3.5%) | 490 (4.1%) | 108,997 (3.5%) | <0.001 |
Dialysis and Type of Procedure | ||||
Dialysis general | 430,856 (13.6%) | 1956 (16.3%) | 428,900 (13.6%) | <0.001 |
Hemofiltration | 100,537 (3.2%) | 453 (3.8%) | 100,084 (3.2) | <0.001 |
Hemodialysis | 365,604 (11.6%) | 1684 (14.1%) | 363,920 (11.6%) | <0.001 |
Hemodiafiltration | 122,393 (3.9%) | 554 (4.6%) | 121,839 (3.9%) | <0.001 |
Serious Adverse events through Hospitalization | ||||
Gastro-intestinal bleeding | 123,962 (3.9%) | 509 (4.2%) | 123,453 (3.9%) | 0.065 |
Intracranial bleeding | 17,022 (0.5%) | 78 (0.7%) | 16,944 (0.5%) | 0.088 |
Myocardial infarction | 206,810 (6.5%) | 562 (4.7%) | 206,248 (6.5%) | <0.001 |
Ischemic Stroke | 70,796 (2.2%) | 237 (2.0%) | 70,559 (2.2%) | 0.057 |
Pulmonary embolism | 51,699 (1.6%) | 195 (1.6%) | 51,504 (1.6%) | 0.995 |
Transfusion of erythrocytes | 973,186 (30.8%) | 4175 (34.8%) | 969,011 (30.8%) | 0.001 |
Primary Endpoint | ||||
In-hospital mortality | 913,283 (28.9%) | 2645 (22.1%) | 910,638 (28.9%) | <0.001 |
Univariate Regression Model | Multivariate Regression Model * | |||
---|---|---|---|---|
OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
In-hospital mortality | 0.70 (0.67–0.73) | <0.001 | 0.75 (0.72–0.79) | <0.001 |
Acute myocardial infarction | 0.70 (0.65–0.77) | <0.001 | 0.62 (0.57–0.68) | <0.001 |
Ischemic Stroke | 0.88 (0.77–1.02) | 0.053 | 0.85(0.75–0.97) | 0.013 |
Deep venous thrombosis or thrombophlebitis | 1.31 (1.16–1.48) | <0.001 | 1.29 (1.14–1.45) | <0.001 |
Pulmonary embolism | 0.99 (0.86–1.15) | 0.947 | 0.94 (0.81–1.08) | 0.354 |
Intracerebral bleeding | 1.21 (0.97–1.510) | 0.092 | 0.97 (0.77–1.22) | 0.802 |
Gastro-intestinal bleeding | 1.09 (0.99–1.19) | 0.064 | 1.06 (0.97–1.16) | 0.196 |
Transfusion of blood constituents | 1.20 (1.16–1.25) | <0.001 | 1.07 (1.03–1.20) | 0.001 |
Initiation of dialysis | 1.24 (1.18–1.30) | <0.001 | 0.93 (0.88–0.98) | 0.004 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wild, J.; Hobohm, L.; Münzel, T.; Wenzel, P.; Steinbrink, K.; Karbach, S.; Keller, K. Psoriasis and Its Impact on In-Hospital Outcome in Patients Hospitalized with Acute Kidney Injury. J. Clin. Med. 2020, 9, 3004. https://doi.org/10.3390/jcm9093004
Wild J, Hobohm L, Münzel T, Wenzel P, Steinbrink K, Karbach S, Keller K. Psoriasis and Its Impact on In-Hospital Outcome in Patients Hospitalized with Acute Kidney Injury. Journal of Clinical Medicine. 2020; 9(9):3004. https://doi.org/10.3390/jcm9093004
Chicago/Turabian StyleWild, Johannes, Lukas Hobohm, Thomas Münzel, Philip Wenzel, Kerstin Steinbrink, Susanne Karbach, and Karsten Keller. 2020. "Psoriasis and Its Impact on In-Hospital Outcome in Patients Hospitalized with Acute Kidney Injury" Journal of Clinical Medicine 9, no. 9: 3004. https://doi.org/10.3390/jcm9093004